E-mail us: service@prospectnews.com Or call: 212 374 2800
Bank Loans - CLOs - Convertibles - Distressed Debt - Emerging Markets
Green Finance - High Yield - Investment Grade - Liability Management
Preferreds - Private Placements - Structured Products
 
Add to balance / Manage account  User:  Log out
Prospect News home > News index > List of issuers A > Headlines for Ariad Pharmaceuticals Inc. > News item
Published on 10/19/2006 in the Prospect News Biotech Daily.

Ariad to sell to 3,112,945 shares in follow-on via Credit Suisse

By Ronda Fears

Memphis, Oct. 19 - After Thursday's closing bell, Ariad Pharmaceuticals, Inc. announced plans to sell 3,112,945 shares in a follow-on offering via bookrunner Credit Suisse Securities (USA) LLC.

There will be a greenshoe of 466,942 shares available.

Cambridge, Mass.-based Ariad develops breakthrough medicines to treat cancer by regulating cell signaling with small molecules.


© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.